Synthetic Biology Services
Online inquiry
Custom mRNA Synthesis

Antibody mRNA

product-img

Introduction Product List Product Features Application Q&A

Introduction

Antibodies are immunoglobulins produced by B lymphocytes during their differentiation into plasma cells that bind specifically to the corresponding antigen. Antibodies can be divided into five major classes (IgG, IgA, IgM, IgD, IgE), which have a protective effect on the organism. Antibody mRNAs don't require nuclear localisation to mediate protein translation, but can be translated directly into target proteins or immunogenic activation of the immune response in vivo by using genetic sequence of the virus. It is obvious that using antibody RNA instead of viral antigen to activate the specific immune response is much safer and free from the risk of infection, which explains why antibody mRNA drugs such as mRNA vaccines are now a hot and mainstream research area. Creative Biolabs provides you with a wide range of antibody mRNA products, mainly for applications in antibody action mechanism and gene therapy drug development. Our different antibody mRNA products are further categorised according to different modification strategies to meet more experimental needs, including nucleoside modifications (eg. N1-methyl-pseudo-UTP, 5-Methyl-CTP & Pseudo-UTP and Pseudo-UTP), 3' end poly(A) length (e.g. 30 nt or 120 nt) and 5' cap end types(e.g. Cap0 or Cap1).

Based on the specificity and diversity of antibodies, Creative Biolabs offers customisation service for specific antibody mRNAs. Creative Biolabs has a team of professionals who can design and customise the most suitable synthetic template to your needs. Our customisation service allows for not only the customisation of long chain antibody mRNAs containing thousands of bases, but also for specific designs through various modification methods such as capping at the 5' end, introduction of poly(A) tails and nucleotide modifications. Creative Biolabs is committed to providing a range of high quality, high purity and high stability antibody mRNA products. If you are interested in our products, please feel free to contact us.

Product List

>>>Can't find what your looking for? Contact us and we will be happy to help.

Product Features

  • Strict Quality Control Standards
    • Multiple quality control standards.
    • High stability and batch-to-batch consistency.
    • Excellent purity and stability profile.
  • Efficient and Time-saving
    • Pre-designed capping and poly (A) tail modification.
    • Shorter turnaround time.

Application

  • Therapeutic Antibodies Development: Antibody mRNAs are used in the development of therapeutic antibodies. The mRNA of an antibody producing cell is isolated. Through reverse transcription, a cDNA library is made. Antibodies can then be produced in vitro for use in therapies and vaccines.
  • Vaccine Design: mRNA-encoded antibody has been sought after for passive immunization strategies. Scientists can use this approach to deliver mRNA-encoded antibodies that can neutralize pathogens such as viruses and bacteria, potentially improving vaccine design.
  • Immunotherapy: Cancer immunotherapy strategies can also benefit from the use of antibody mRNAs. Creating personalized therapeutic antibodies using this approach can enhance the targeting of cancer cells, potentially improving treatment efficacy.
  • Diagnostic Assays: Antibody mRNAs can be utilized in diagnostic assays, where they serve as a surrogate marker for the presence of specific cells or pathogens. For instance, the mRNA coding for a specific antibody can indicate the presence of a specific cell type or pathogen in a patient's blood sample.
  • Antibody Production: Antibody mRNAs can be used as a template for the in vitro production of monoclonal antibodies, which can be used in various therapeutic and diagnostic applications.

Q&A

Q: How do you design an mRNA construct for expressing a specific antibody?

A: To design an mRNA construct for expressing a specific antibody, first, identify the DNA sequences encoding the heavy and light chains of the antibody. These sequences are then reverse-transcribed into mRNA sequences. A strong promoter, such as the T7 promoter for in vitro transcription, is included to drive robust expression. Additionally, a 5' cap structure and a 3' poly(A) tail are essential for stability and efficient translation in the cytoplasm.

Q: Does the antibody mRNA have a direct role in pathogen neutralization?

A: The antibody mRNA itself does not have a direct role in neutralizing the pathogen. However, it codes for the antibody protein, which binds to specific antigens on the pathogen and neutralizes it.

Q: Does the antibody mRNA have a direct role in pathogen neutralization?

A: The antibody mRNA itself does not have a direct role in neutralizing the pathogen. However, it codes for the antibody protein, which binds to specific antigens on the pathogen and neutralizes it.

Q: What factors can influence the translation efficiency of antibody mRNA into protein?

A: Factors such as codon bias, mRNA secondary structure, availability of translation machinery, and the RNA sequence around the start codon can impact the translation efficiency.

Q: How to determine which cells are producing specific antibody mRNA?

A: Techniques such as in-situ hybridization or single-cell RNA sequencing can be employed to identify which cells are producing specific antibody mRNA.

Q: Could antibody mRNA be used to identify different antibody isotypes?

A: Yes, since each isotype has distinctive constant regions, the specific antibody mRNA encoding these regions can be used to identify different antibody isotypes.

Q How to measure the transcript level of antibody mRNA in a cell?

A: Quantitative polymerase chain reaction (qPCR) or RNA sequencing (RNA-seq) are commonly used techniques to measure the level of specific mRNA transcripts within a cell, including that of antibody mRNA.

Q: What method is used to synthesize antibody mRNA?

A: Antibody mRNA is typically synthesized using in vitro transcription (IVT). This process involves a DNA template containing the T7 promoter upstream of the antibody coding sequence. IVT kits facilitate the synthesis of capped and tailed mRNA, which is crucial for stability and translation efficiency in eukaryotic cells.

Q: How can you ensure the stability of antibody mRNA in vitro and in vivo?

A: Stability can be enhanced by incorporating modifications such as the addition of a 5' cap, a 3' poly(A) tail, and optimized untranslated regions (UTRs). Modified nucleotides like pseudouridine or methylated cytosine can also be used to reduce innate immune responses and increase mRNA stability.

Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2130
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript 2857916
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript (131)I-chTNT-1/B
Category (CDS) Antibody
Applications Gene therapy research
Product type mRNA
Transcript (131)I-chTNT-1/B
Category (CDS) Antibody
Applications Gene therapy research
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW